Lost password ?
Novasep will produce the active substance of the vaccine in its Belgian facilities
This agreement covers the manufacturing of the Adeno-Associated Virus (AAV)
In response to the rapidly developing Covid-19 epidemic, governments around the world are strengthening preventive and precautionary measures to limit the spread of the virus and protect populations.
The new Biopharma Solutions Business Unit is created to support Novasep’s growth strategy, Rise-2, and includes all Novasep Belgium activities. Cédric Volanti has joined Novasep to lead this new BU and will be a member of Novasep’s Executive Committee.
A fire broke out this morning around 4:20 am outside of a small production workshop at our site in Chasse-sur-Rhône.
Leveraging on its recent investments Senrise-IV and Senefill, Novasep launches a unique
2-year turnkey plant offer to accelerate commercial production of viral vectors.
Senefill will be commissioned on October 1, 2019 and will offer Fill & Finish clinical and commercial services for biological products, from formulation to packaging.
This agreement supports the growing demand for lentivector-based gene therapies, immunotherapies and vaccines
• All resolutions were approved by 100% of the participating Noteholders and C Warrantholders
• Noteholders representing 99.9% of total outstanding principal amount participated
Novasep, a leading supplier of services and technologies for the life sciences industry, announces Enzene Biosciences (India) has chosen BioSC® Pilot for purification of biopharmaceuticals to operate in its Pune plant.